Merck & Co., Inc. (MRK) announced the European Commission, or EC, approval of ELONVA, or corifollitropin alfa injection. ELONVA is indicated for controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program. ELONVA is the first sustained follicle stimulant.
With the EC approval, Merck receives marketing authorization for ELONVA with unified labeling valid in all European Union Member States.
For comments and feedback: editorial@rttnews.com